Info

Sunesis Pharmaceuticals, Inc. (Sunesis) is a clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of small molecule therapeutics for use in oncology and other diseases. As of December 31, 2007, the Company was advancing three oncology product candidates: SNS-595, SNS-032 and SNS-314, through in-house research and development. The Company’s lead product candidate, SNS-595, is a naphthyridinone analog. With SNS-595, Sunesis was conducting one Phase II single agent clinical trial in platinum-resistant ovarian cancer patients and one Phase Ib combination clinical trial with cytarabine in patients with acute myeloid leukemia who are relapsed (progressed after a period of response to treatment) or refractory (resistant to treatment) as of December 31, 2007. In December 2007, the Company announced that it had entered into a collaborative research agreement with the Multiple Myeloma Research Consortium.(Source: 10-K)